SM
UTHR icon

Sabby Management’s United Therapeutics UTHR Stock Holding History

Sabby Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-53,116
Closed -$6.78M – 206
2017
Q2 		$6.89M Buy
53,116
+35,774
+206% +$4.46M 0.45% 31
2017
Q1 		$2.35M Buy
+17,342
New +$2.63M 0.13% 78
2016
Q4 		– Sell
-28,112
Closed -$3.59M – 331
2016
Q3 		$3.32M Buy
+28,112
New +$3.38M 0.12% 96
2016
Q1 		– Sell
-34,779
Closed -$4.4M – 353
2015
Q4 		$5.45M Buy
+34,779
New +$5.06M 0.3% 57

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management's UTHR Position: Q3 2017 in Review

Sabby Management sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 53,116 shares — an estimated $6.78M sold.

Sabby Management first reported a position in UTHR in Q4 2015 and held it in 4 quarters. The position peaked at $6.89M in Q2 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Sabby Management reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 53,116 United Therapeutics shares in Q3 2017, an estimated $6.78M.
  • Sabby Management first reported a position in United Therapeutics in Q4 2015 and held it in 4 quarters.
  • Sabby Management's United Therapeutics position peaked at $6.89M in Q2 2017.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.